Fact based stock research
Jointown Pharmaceutical (SHSE:600998)

CNE100000W45



Due to the geopolitical instabilities, research on companies located in authoritarian regimes has been discontinued. Research at Obermatt is limited to companies in democracies as measured by The Economist Intelligence Unit Democracy Index.



Jointown Pharmaceutical stock research in summary

jzteyao.com


There is no stock research analysis by the purely financial fact-based Obermatt method for: Jointown Pharmaceutical (SHSE:600998), Health Care Distributors, China. Contact us if you would like research on this stock.


Latest Obermatt Ranks


Value Rank n/a
Growth Rank n/a
Safety Rank n/a
Combined Rank n/a
Country China
Industry Health Care Distributors
Index
Size class XX-Large

February 24, 2022. Stock data may be delayed. Login to get the most recent research.

Add to Watchlist
Filter Similar Stocks
Similar Top 10

Research History: Jointown Pharmaceutical

RESEARCH HISTORY 2019 2020 2021 2022
VALUE
VALUE 73
62
100
n/a
GROWTH
GROWTH 61
83
31
n/a
SAFETY
SAFETY 59
69
61
n/a
COMBINED
COMBINED 83
89
90
n/a

Last update of Combined Rank: 24-Feb-2022. Financial reporting date used for calculating ranks: 30-Sep-2021. Stock research history is based on the Obermatt Method. The higher the rank, the better Jointown Pharmaceutical is in the corresponding investment strategy.


Value Metrics in Detail

VALUE METRICS 2019 2020 2021 2022
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S) 91
81
87
n/a
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E) 67
85
87
n/a
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book) 78
64
82
n/a
DIVIDEND YIELD
DIVIDEND YIELD 28
1
84
n/a
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE 73
62
100
n/a

Last update of Value Rank: 24-Feb-2022. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Jointown Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2019 2020 2021 2022
REVENUE GROWTH
REVENUE GROWTH 70
72
50
n/a
PROFIT GROWTH
PROFIT GROWTH 56
72
83
n/a
STOCK RETURNS
STOCK RETURNS 40
82
32
n/a
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH 61
83
31
n/a

Last update of Growth Rank: 30-Sep-2021. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Jointown Pharmaceutical.


Safety Metrics in Detail

SAFETY METRICS 2019 2020 2021 2022
LEVERAGE
LEVERAGE 30
42
34
n/a
REFINANCING
REFINANCING 98
98
94
n/a
LIQUIDITY
LIQUIDITY 41
50
65
n/a
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY 59
69
61
n/a

Last update of Safety Rank: 18-Feb-2022. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Jointown Pharmaceutical and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Jointown Pharmaceutical from February 24, 2022.


We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.